Author

Arnd Mueller

Observed institution: Teva Pharmaceuticals (Germany)

OpenAlex ID: A5069628221

Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART)

2016 · Thomas Strowitzki, Waldemar Kuczynski, et al. · Reproductive Biology and Endocrinology · 89

Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study

2016 · Thomas Strowitzki, Waldemar Kuczynski, et al. · Reproductive Biology and Endocrinology · 30

Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap® (XM17), Comparability with Gonal-f®, and Performance/Consistency

2017 · Rainer Winstel, Juergen Wieland, et al. · Drugs in R&D · 14

Phase I, two-way, crossover study to demonstrate bioequivalence and to compare safety and tolerability of single-dose XM17 vs Gonal-f® in healthy women after follicle-stimulating hormone downregulation

2015 · Andreas Lammerich, Arnd Mueller, et al. · Reproductive Biology and Endocrinology · 9

Real-World Osilodrostat Effectiveness and Safety in Nonpituitary Cushing Syndrome

2025 · Antoine Tabarin, Jérôme Bertherat, et al. · The Journal of Clinical Endocrinology & Metabolism · 5

Comment on “Biosimilar FSH preparations- are they identical twins or just siblings?”

2016 · Thomas Strowitzki, Waldemar Kuczynski, et al. · Reproductive Biology and Endocrinology · 1

SUN-073 Long-Term Safety of Pasireotide in Patients With Cushing's Disease: Final Results From a 10-Year Open-Label Phase IV Rollover Study (B2412)

2025 · Wilson Gallardo, Christophe De Block, et al. · Journal of the Endocrine Society

SUN-071 Long-term Safety and Effectiveness of Osilodrostat in Patients with Cushing’s Disease in the LINC Rollover Study

2025 · Richard Joseph Auchus, Przemysław Witek, et al. · Journal of the Endocrine Society

SUN-054 Long-Term, Real-World, Safety and Effectiveness of Osilodrostat In Patients With Pituitary and Non-Pituitary Cushing’s Syndrome: 2-Year Interim Data From LINC 6

2025 · Irina Bancos, Frédéric Castinetti, et al. · Journal of the Endocrine Society

SAT-563 PASIPHY: Phase II Study to Evaluate the Efficacy and Safety of Pasireotide Treatment for Patients With Post-bariatric Hypoglycemia

2025 · Tracey McLaughlin, Andreea Ciudin, et al. · Journal of the Endocrine Society

Long-term safety of pasireotide in patients with acromegaly: final results from a 10-year open-label phase iv rollover study (B2412)

2025 · Gadelha Monica R., Elena Grineva, et al. · Endocrine Abstracts

Phase II study to assess the efficacy and safety of pasireotide in patients with post-bariatric hypoglycaemia: PASIPHY study design

2025 · Andreea Ciudin, Tracey McLaughlin, et al. · Endocrine Abstracts

Safety and effectiveness of >8 years of osilodrostat treatment in patients with cushing's disease: findings from the LINC rollover open-label, multicentre study

2025 · Rosario Pivonello, Przemyslaw Witek, et al. · Endocrine Abstracts

Osilodrostat prior and new use in patients with endogenous cushing's syndrome: 2-year interim analysis results (safety and effectiveness) from the real-world non-interventional LINC 6 study

2025 · Nicolas Scheyer, Frederic Castinetti, et al. · Endocrine Abstracts

Long-term safety and efficacy of subcutaneous pasireotide in patients with cushing's disease: results from a non-interventional study

2024 · Fausto Bogazzi, Salvatore Cannavo, et al. · Endocrine Abstracts

Works count: 15

Citation count: 148

H-index: 5

I10-index: 3